CTLA4 and neoplasm: CTLA4 blockade using the specific antagonistic monoclonal antibodies ipilimumab (formerly known as MDX010 and BMS734016) and tremelimumab (formerly known as CP-675,206 and ticilimumab) reproducibly induce objective tumor responses in a subset of patients with melanoma [7-15].